leisure time -WSS

leisure time

author：entertainment 2025-09-29 22:47:46 - browse：54863

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： The untold story of TV’s first prescription drug ad

WSS

Study identifies new proteins linked to dementia risk 25 years later

Hospitals struggle to profit from CAR

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

State of the Union pitch: Bigger Medicare drug price negotiations

Judge rejects Trump's request to move Stormy Daniels hush

Ancient Greek ideas underpin modern concepts of pregnancy

hotspot

leisure time

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

7 more heat

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pregnant women don't need prenatal multivitamins, study concludes

Hollywood unions extend contract negotiations for actors

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Hepatitis C has a cure — but many Americans still lack access to it

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare drug price negotiation hearing pits pharma v Biden admin

Wikipedia

Readout Newsletter: BridgeBio, Akero, and human embryo models

Medicare drug price negotiation continues, as pharma counteroffers

Ending racial health disparities hinges on penalties, political will

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Driven by the pandemic, applicants flood public health schools

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

knowledge

hotspot

explore

entertainment